63 Top Dividend Growth Stocks For May 2025
I present 63 high-quality dividend growth stocks for investment for May 2025, categorized by yield: High (4%+), Medium (2.5-3.9%), and Low (
Fiscal Year: July - June
Cardinal Health, Inc. (CAH), listed on the NYSE, has a market capitalization of $26.55B. As of May 20, 2025, the stock is trading at $153.86 per share, offering investors a clear view of its current market value. Cardinal Health, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 24.12, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Cardinal Health, Inc. also offers a dividend yield of 1.33%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Cardinal Health, Inc. (CAH) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Cardinal Health, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Cardinal Health, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Cardinal Health, Inc. is 15.03, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Cardinal Health, Inc. (CAH) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Cardinal Health, Inc. (CAH) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Cardinal Health, Inc. (CAH) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Cardinal Health, Inc.. To access the full SS Score, consider upgrading your subscription.
Cardinal Health, Inc. is a significant player in the industry sector, with a market capitalization of $26.55B and a competitive P/E ratio of 24.12. Investors should compare these metrics with industry peers to gauge whether Cardinal Health, Inc. is outperforming or underperforming within its sector.
Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio , May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizin...
DUBLIN, Ohio , May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Comp...
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Industrial engineering company Parker-Hannifin announced i...
Cardinal Health Inc. CAH on Thursday reported third-quarter 2025 adjusted EPS of $2.35, up 13% year over year, beating the consensus of $2.17.
Cardinal Health, Inc. (NYSE:CAH) Q3 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aar...
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast for the fourth time, betting on strong demand for costly specialty medicines and branded drugs.
Revenue was flat at $54.9 billion; revenue increased 19% excluding the impact of the previously communicated customer contract expiration GAAP 1 operating earnings were $730 million; GAAP diluted EPS ...
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Cardinal Health, Atmos Energy, and General Mills make the cut for one ESG fund manager.
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...
DUBLIN, Ohio , March 25, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2025 on May 1, prior to the opening of trading on the New...
Cardinal Health, Inc. (NYSE:CAH) Leerink's 2025 Global Healthcare Conference Call March 12, 2025 8:40 AM ET Company Participants Aaron Alt - Chief Financial Officer Matt Sims - Investor Relations Con...
DUBLIN, Ohio , March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Health...
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval...
Cardinal Health CAH reported better-than-expected second-quarter financial results on Thursday.
Cardinal Health, Inc. (NYSE:CAH) Q2 2025 Earnings Conference Call January 30, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Office...
Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast as strong demand for costly specialty medicines and branded drugs drove sales at its pharmaceuticals unit.
Revenue decreased 4% to $55.3 billion; revenue increased 16% excluding the impact of the previously communicated large customer contract expiration GAAP 1 operating earnings were $549 million; GAAP di...
Cardinal Health, Inc. (NYSE:CAH) J.P. Morgan Healthcare Conference January 14, 2025 12:00 PM ET Company Participants Aaron Alt - CFO Jason Hollar - CEO Conference Call Participants Lisa Gill - JPMorg...
New facility will be outfitted with latest robotics and automation technologies DUBLIN, Ohio , Jan. 14, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced construction is underway on a new dis...
Cardinal Health said on Tuesday it expects annual profit to be at the higher end of its previous forecast range, primarily driven by strong demand for costly specialty medicines and branded drugs at i...
BofA Securities predicts that headline risks affecting the Healthcare Tech & Distribution sector in 2024 will likely continue in 2025.
Dublin, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The "Canada Personal Protective Equipment Market Outlook to 2033 - Gloves, Gowns, Masks, Shoe Covers and Others" report has been added to ResearchAndMarkets.c...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 1.35B | Analyst x6 | |
2026 | 1.89B | 39.80% | Analyst x6 |
2027 | 2.30B | 22.10% | Analyst x5 |
2028 | 2.34B | 1.36% | Analyst x2 |
2029 | 3.31B | 41.62% | Analyst x1 |
2030 | 3.63B | 9.78% | Est @9.8% |
2031 | 3.90B | 7.46% | Est @7.5% |
2032 | 4.13B | 5.84% | Est @5.8% |
2033 | 4.31B | 4.40% | Est @4.4% |
2034 | 4.47B | 3.65% | Est @3.7% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 2.36B | 1.00 | 2.36B |
2024A | 3.25B | 1.00 | 3.25B |
2025E | 1.35B | 1.08 | 1.25B |
2026E | 1.89B | 1.17 | 1.61B |
2027E | 2.30B | 1.27 | 1.82B |
2028E | 2.34B | 1.37 | 1.70B |
2029E | 3.31B | 1.49 | 2.22B |
2030E | 3.63B | 1.61 | 2.25B |
2031E | 3.90B | 1.74 | 2.24B |
2032E | 4.13B | 1.89 | 2.19B |
2033E | 4.31B | 2.04 | 2.11B |
2034E | 4.47B | 2.21 | 2.02B |
Terminal | 79.41B | 2.21 | 35.88B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.